The company's breakthrough potential comes not from collecting raw DNA, but from linking it at an individual level to a rich set of "phenotype" data, including proteomics, metabolomics, and transcriptomics. This deep, multi-layered dataset from novel populations is what unlocks actionable insights for drug discovery.

In AI for science, the true competitive advantage lies in generating unique, high-quality experimental data from self-driving labs. The AI models themselves are becoming commoditized, while the physical data remains the defensible asset.

With powerful LLMs, reasoning, and inference becoming commoditized, the key differentiator for AI-powered products is no longer the model itself. The most critical factor for success is the quality of the underlying data. Unifying, protecting, and ensuring the accessibility of high-quality data is the primary challenge.

Unlike text-based LLMs where simply increasing parameter count works, Verge Labs found the biggest AI performance gains in biology come from scaling data modalities—adding new types of data like proteomics and imaging. Fusing different data sources is more critical than just making the model bigger.

The next inflection point will come from clever data generation strategies optimized for AI models, not human analysis. This "black box data" approach—like pooled screening with sequencing readouts—is vastly more scalable and creates a powerful, proprietary moat for companies.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

The competitive advantage in pharma isn't the sophistication of an AI algorithm, which is often a commodity built on third-party models. The true differentiator is the quality, relevance, and end-to-end consistency of the proprietary data used to train and validate these models. Poor data invalidates even the best analytics.

Unlike general AI which leverages vast, existing datasets, Noetik believes progress in biology requires designing and generating specific, high-quality data with foresight into the models that will be trained. They compare this to the intentional, decades-long creation of the PDB dataset for protein folding.

Haya's AI platform is differentiated by its focus on deconvoluting the "dark genome" to identify completely novel, "first-in-biology" targets. This contrasts with AI applications that merely optimize molecules for known biological pathways or targets.